A Phase 3 interventional study of DE-109 44 ug and DE-109 440 ug in Uveitis; Posterior, Disorder, sponsored by Santen Inc.. Completed at 151 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-16.
Sponsored by Santen Inc. (part of Santen Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Uveitis with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Uveitis · United States.
Among the 139 studies in Uveitis with a site in United States, this one has the largest enrollment of the 100 interventional ones that give a count, is one of 7 that started in 2011, is one of 31 in phase 3, and was the 72nd registered.
300 studies on the registry are indexed under Uveitis; 33 are open to participants now.
Browse Uveitis studies →7 of the 139 studies in Uveitis with a site in United States are open now. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages up to 17
Quan Dong Nguyen · Sites in United States
Ages 18–70
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in United States, Australia, China
Ages 18–65
Meyer Children's Hospital IRCCS · Sites in United States, Belgium, Greece and 2 more countries
Ages 1–16
The Cleveland Clinic · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 40 · Phase 3 31 · Phase 4 9
First in 1987; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 592 is above the median of 30 across 175 interventional studies indexed under Uveitis.
Median enrollment 19 across the 100 interventional studies, 123 across the 36 observational. Of the 117 that completed or were terminated, 50 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 139 have an industry lead sponsor. The 10 most frequent:
This study is registered under Santen Inc., one of the names counted as Santen Pharmaceutical Co., Ltd.. Under that name alone:
Santen Inc. is the lead sponsor of 32 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Santen Pharmaceutical Co., Ltd. has 3 studies filed under Uveitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Uveitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07518134Jaeb Center for Health ResearchA Study of Uveitis in Children <18 Years of Age | 2027-04-01 |
| NCT04704609The Cleveland ClinicImaging Quantification of Inflammation (IQI) | 2027-04-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 139 studies in Uveitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DE-109 44 ug
Drug: DE-109 440 ug
Drug: DE-109 880 ug
Low dose
Also known as: Sirolimus
Medium dose
Also known as: Sirolimus
High dose
Also known as: Sirolimus
The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0 = No inflammation
Time frame: Day1 (Baseline) and Month 5 (Day150)
VH 0 or 2-unit Response: Having a Reduction (Improvement) of at Least 2 Units From Baseline in VH Score or a VH Score of 0 at Month 5 (Modified SUN Scale)
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible
Time frame: Day1/Baseline and Day150/Month 5
VH 0 or 0.5+ Response: Having a VH Score of 0 or 0.5+ at Month 5 (Modified SUN Scale)
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0.5+=Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)
Time frame: Day1/Baseline and Day150/Month 5
VH 0 Response at Month 6: Having a VH Score of 0 at Month 6 (Modified SUN Scale)
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0 = No inflammation
Time frame: Day1/Baseline and Day180/Month 6
VH 0 or 2-unit Response at Month 6: Having a VH Score of 0 or a Decrease (Improvement) of at Least 2 Units From Baseline in VH Score at Month 6 (Modified SUN Scale)
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible
Time frame: Day1/Baseline and Day180/Month 6
VH 0 or 0.5+ Response at Month 6: Having a VH Score of 0 or 0.5+ at Month 6 (Modified SUNscale)
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible
Time frame: Day1/Baseline and Day180/Month 6
| Milestone | DE-109 44 μg | DE-109 440 μg | DE-109 880 μg |
|---|---|---|---|
| Started | 208 | 208 | 176 |
| Completed | 175 | 162 | 137 |
| Not completed | 33 | 46 | 39 |
| Milestone | DE-109 44 μg | DE-109 440 μg | DE-109 880 μg |
|---|---|---|---|
| Started | 119 | 102 | 114 |
| Completed | 63 | 58 | 44 |
| Not completed | 56 | 44 | 70 |
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0 = No inflammation
| Participants | DE-109 44 µg | DE-109 440 µg | DE-109 880 µg |
|---|---|---|---|
| The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5 | 28 | 44 | 27 |
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible
| Participants | DE-109 44 µg | DE-109 440 µg | DE-109 880 µg |
|---|---|---|---|
| VH 0 or 2-unit Response: Having a Reduction (Improvement) of at Least 2 Units From Baseline in VH Score or a VH Score of 0 at Month 5 (Modified SUN Scale) | 43 | 56 | 33 |
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0.5+=Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)
| Participants | DE-109 44 µg | DE-109 440 µg | DE-109 880 µg |
|---|---|---|---|
| VH 0 or 0.5+ Response: Having a VH Score of 0 or 0.5+ at Month 5 (Modified SUN Scale) | 84 | 104 | 70 |
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0 = No inflammation
| Participants | DE-109 44 µg | DE-109 440 µg | DE-109 880 µg |
|---|---|---|---|
| VH 0 Response at Month 6: Having a VH Score of 0 at Month 6 (Modified SUN Scale) | 29 | 43 | 51 |
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible
| Participants | DE-109 44 µg | DE-109 440 µg | DE-109 880 µg |
|---|---|---|---|
| VH 0 or 2-unit Response at Month 6: Having a VH Score of 0 or a Decrease (Improvement) of at Least 2 Units From Baseline in VH Score at Month 6 (Modified SUN Scale) | 42 | 52 | 26 |
At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex) 1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+ 2. Moderate blurring of the optic nerve head 3. Marked blurring of the optic nerve head 4. Optic Nerve head not visible
| Participants | DE-109 44 µg | DE-109 440 µg | DE-109 880 µg |
|---|---|---|---|
| VH 0 or 0.5+ Response at Month 6: Having a VH Score of 0 or 0.5+ at Month 6 (Modified SUNscale) | 81 | 90 | 66 |
Collected over Adverse events - begin capturing once the first treatment is given. Per Schedule of Events through study completion, up to 24 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DE-109 44 µg - Double Masked | 1/207 (0.5%) | 41/207 (19.8%) | 165/207 (79.7%) |
| DE-109 440 µg - Double Masked | 0/205 (0%) | 45/205 (22%) | 166/205 (81%) |
| DE-109 880 µg - Double Masked | 0/178 (0%) | 38/178 (21.3%) | 148/178 (83.1%) |
| DE-109 880 µg - Open-Label | 0/321 (0%) | 59/321 (18.4%) | 210/321 (65.4%) |
| Event | DE-109 44 µg - Double Masked | DE-109 440 µg - Double Masked | DE-109 880 µg - Double Masked | DE-109 880 µg - Open-Label |
|---|---|---|---|---|
| UveitisEye disorders | 6/207 | 10/205 | 13/178 | 5/321 |
| Non-infectious endophthalmitisEye disorders | 0/207 | 1/205 | 7/178 | 11/321 |
| ChoroiditisEye disorders | 8/207 | 4/205 | 3/178 | 6/321 |
| Medication residueGeneral disorders | 2/207 | 2/205 | 4/178 | 6/321 |
| CataractEye disorders | 4/207 | 2/205 | 3/178 | 4/321 |
| Intermediate uveitisEye disorders | 0/207 | 0/205 | 3/178 | 0/321 |
| Intraocular pressure increasedInvestigations | 3/207 | 3/205 | 3/178 | 3/321 |
| Visual acuity reducedEye disorders | 1/207 | 3/205 | 0/178 | 0/321 |
| VitritisEye disorders | 2/207 | 2/205 | 0/178 | 4/321 |
| EndophthalmitisInfections and infestations | 0/207 | 1/205 | 1/178 | 4/321 |
| Event | DE-109 44 µg - Double Masked | DE-109 440 µg - Double Masked | DE-109 880 µg - Double Masked | DE-109 880 µg - Open-Label |
|---|---|---|---|---|
| Intraocular pressure increasedInvestigations | 34/207 | 34/205 | 43/178 | 44/321 |
| IridocyclitisEye disorders | 31/207 | 32/205 | 30/178 | 31/321 |
| UveitisEye disorders | 19/207 | 15/205 | 29/178 | 15/321 |
| Conjunctival haemorrhageEye disorders | 22/207 | 19/205 | 26/178 | 24/321 |
| Eye painEye disorders | 18/207 | 22/205 | 19/178 | 14/321 |
| CataractEye disorders | 11/207 | 8/205 | 13/178 | 32/321 |
| Intermediate uveitisEye disorders | 16/207 | 15/205 | 14/178 | 9/321 |
| Cystoid macular oedemaEye disorders | 12/207 | 15/205 | 11/178 | 7/321 |
| Cataract subcapsularEye disorders | 3/207 | 10/205 | 12/178 | 17/321 |
| HeadacheNervous system disorders | 7/207 | 12/205 | 4/178 | 7/321 |
| Age, Categorical(Participants) | DE-109 44 µg | DE-109 440 µg | DE-109 880 µg | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 188 | 191 | 153 | 532 |
| >=65 years | 20 | 17 | 23 | 60 |
| Sex: Female, Male(Participants) | DE-109 44 µg | DE-109 440 µg | DE-109 880 µg | Total |
|---|---|---|---|---|
| Female | 113 | 117 | 113 | 343 |
| Male | 95 | 91 | 63 | 249 |
| Race (NIH/OMB)(Participants) | DE-109 44 µg | DE-109 440 µg | DE-109 880 µg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 1 | 3 | 8 |
| Asian | 76 | 77 | 72 | 225 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 2 |
| Black or African American | 16 | 13 | 13 | 42 |
| White | 93 | 99 | 79 | 271 |
| More than one race | 8 | 7 | 3 | 18 |
| Unknown or Not Reported | 10 | 10 | 6 | 26 |
| Region of Enrollment(Participants) | DE-109 44 µg | DE-109 440 µg | DE-109 880 µg | Total |
|---|---|---|---|---|
| Colombia | 4 | 4 | 5 | 13 |
| Argentina | 20 | 13 | 10 | 43 |
| United States | 70 | 71 | 45 | 186 |
| Japan | 4 | 8 | 6 | 18 |
| United Kingdom | 4 | 8 | 4 | 16 |
| India | 69 | 65 | 65 | 199 |
| Spain | 0 | 1 | 2 | 3 |
| Austria | 3 | 2 | 0 | 5 |
| Turkey | 4 | 2 | 0 | 6 |
| Brazil | 2 | 3 | 5 | 10 |
| Poland | 1 | 3 | 2 | 6 |
| Italy | 2 | 7 | 2 | 11 |
| Israel | 7 | 1 | 3 | 11 |
| Chile | 3 | 2 | 4 | 9 |
| France | 4 | 3 | 7 | 14 |
| Peru | 6 | 10 | 10 | 26 |
| Germany | 5 | 5 | 6 | 16 |
Showing the first 100 of 151 sites across 17 countries. Choose a country and city above to see the rest.
The record gives a start of May 2011, a primary completion of Sep 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2019, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus